...
首页> 外文期刊>Annals of allergy, asthma, and immunology >Myocardial infarction during intravenous immunoglobulin infusion in a 65-year-old man with common variable immunodeficiency and subsequent successful repeated administration.
【24h】

Myocardial infarction during intravenous immunoglobulin infusion in a 65-year-old man with common variable immunodeficiency and subsequent successful repeated administration.

机译:一名65岁男性患者,静脉输注免疫球蛋白期间发生心肌梗塞,该患者具有常见的可变免疫缺陷,随后成功重复给药。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Intravenous immunoglobulin (IVIG) may cause thromboembolic events. Although such events are usually associated with large IVIG doses administered to treat neurologic diseases, thromboembolic events may also occur with standard immunodeficiency doses. OBJECTIVE: We describe a 65-year-old man with common variable immunodeficiency (CVID) who experienced angina and myocardial infarction with IVIG infusion. METHODS: The patient's electronic medical record was reviewed. RESULTS: The patient developed substernal chest pain during a scheduled 40-g (400-mg/kg) infusion. The infusion was discontinued, and a cardiac evaluation was initiated. The patient was found to have elevated troponin T and creatine kinase MB levels, signifying cardiac injury. Heart catheterization revealed severe vessel disease, and surgical revascularization was subsequently performed. Three weeks after revascularization, an IVIG dose of 200 mg/kg was cautiously readministered. This dose was increased in 2 weeks to 300 mg/kg, which was tolerated every 3 to 4 weeks without any adverse thrombotic events in the subsequent 12 months. CONCLUSIONS: This case demonstrates not only angina and myocardial infarction associated with IVIG infusion in a patient with CVID but also the successful reinitiation of IVIG infusion after surgical revascularization. This case also underscores the importance of caution with IVIG infusion in patients with CVIDand known coronary artery disease.
机译:背景:静脉免疫球蛋白(IVIG)可能引起血栓栓塞事件。尽管此类事件通常与用于治疗神经系统疾病的大剂量IVIG有关,但在标准免疫缺陷剂量下也可能发生血栓栓塞事件。目的:我们描述了一个65岁的患有普通可变免疫缺陷(CVID)的男性,他通过IVIG输注经历了心绞痛和心肌梗塞。方法:回顾了患者的电子病历。结果:患者在预定的40克(400毫克/千克)输注过程中出现了胸骨下胸痛。中止输注,并开始进行心脏评估。发现该患者的肌钙蛋白T和肌酸激酶MB水平升高,表明心脏受伤。心脏导管检查发现严重的血管疾病,随后进行了手术血运重建。血运重建后三周,谨慎重新给予200 mg / kg的IVIG剂量。该剂量在2周内增加到300 mg / kg,每3至4周可耐受一次,在随后的12个月中无任何不利的血栓形成事件。结论:该病例不仅显示CVID患者IVIG输注相关的心绞痛和心肌梗塞,而且在手术血管重建后成功重新开始IVIG输注。该病例还强调了在CVID和已知冠状动脉疾病患者中进行IVIG输注时要小心的重要性。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号